Skip to main content

Advertisement

SpringerLink
Log in

Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Objective

The usefulness of 2-deoxy-2-[F-18]fluoro-d-glucose (FDG)–positron emission tomography (PET) in monitoring breast cancer response to chemotherapy has previously been reported. Elevated uptake of FDG by treated tumors can persist however, particularly in the early period after treatment is initiated. 3′-[F-18]Fluoro-3′-deoxythymidine (FLT) has been developed as a marker for cellular proliferation and, in principle, could be a more accurate predictor of the long-term effect of chemotherapy on tumor viability. We examined side-by-side FDG and FLT imaging for monitoring and predicting tumor response to chemotherapy.

Methods

Fourteen patients with newly diagnosed primary or metastatic breast cancer, who were about to commence a new pharmacologic treatment regimen, were prospectively studied. Dynamic 3-D PET imaging of uptake into a field of view centered over tumor began immediately after administration of FDG or FLT (150 MBq). After 45 minutes of dynamic acquisition, a clinically standard whole-body PET scan was acquired. Patients were scanned with both tracers on two separate days within one week of each other (1) before beginning treatment, (2) two weeks following the end of the first cycle of the new regimen, and (3) following the final cycle of that regimen, or one year after the initial PET scans, whichever came first. (Median and mean times of early scans were 5.0 and 6.6 weeks after treatment initiation; median and mean times for late scans were 26.0 and 30.6 weeks after treatment initiation.) Scan data were analyzed on both tumor-by-tumor and patient-by-patient bases, and compared to each patient's clinical course.

Results

Mean change in FLT uptake in primary and metastatic tumors after the first course of chemotherapy showed a significant correlation with late (av. interval 5.8 months) changes in CA27.29 tumor marker levels (r = 0.79, P = 0.001). When comparing changes in tracer uptake after one chemotherapy course versus late changes in tumor size as measured by CT scans, FLT was again a good predictor of eventual tumor response (r = 0.74, P = 0.01). Tumor uptake of FLT was near-maximal by 10 minutes after injection. The time frame five to 10 minutes postinjection of FLT produced standardized uptake value (SUV) values highly correlated with SUV values obtained after 45-minute uptake (r = 0.83, P < 0.0001), and changes in these early SUVs after the first course of chemotherapy correlated with late changes in CA27.29 (r = 0.93, P = 0.003).

Conclusion

A 10-minute FLT-PET scan acquired two weeks after the end of the first course of chemotherapy is useful for predicting longer-term efficacy of chemotherapy regimens for women with breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Shields AF, Grierson JR, Dohmen BM, et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334–1336

    Article  PubMed  CAS  Google Scholar 

  2. Lu L, Samuelsson L, Bergstrom M, et al. (2002) Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. J Nucl Med 43:1688–1698

    PubMed  CAS  Google Scholar 

  3. Dittman H, Dohmen BM, Kehibach R, et al. (2002) Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med 29:1462–1469

    Article  CAS  Google Scholar 

  4. Veselle H, Grierson J, Muzi M, et al. (2002) In vivo validation of 3′deoxy-3′-[18F]fluorothymidine ([18F]FLT) as a proliferation imaging tracer in humans: correlation of [18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8:3315–3323

    PubMed  Google Scholar 

  5. Wagner M, Seitz U, Buck A, et al. (2003) 3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation is a murine B-cell lymphoma model and in the human disease. Cancer Res 63:2681–2687

    PubMed  CAS  Google Scholar 

  6. Smyczek-Gargya B, Fersis N, Dittman H, et al. (2004) PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 31:720–724

    Article  PubMed  Google Scholar 

  7. Dittman H, Dohman BM, Paulsen F, et al. (2003) [(18)F]FLT PET for diagnosis and staging of thoracic tumors. Eur J Nucl Med Mol Imaging 30:1407–1412

    Article  PubMed  CAS  Google Scholar 

  8. Satyamurthy N, Amarasekara B, Alvord CW, Barrio JR, Phelps ME (2002) Tantalum 18O-water target for the production of 18F-fluoride with high reactivity for the preparation of 2-desoxy-2-18F-fluoro-d-glucose. Mol Imaging Biol 4:65–70

    Article  PubMed  CAS  Google Scholar 

  9. Blocher A, Kuntzsch M, Wei R, Machulla H (2002) Synthesis and labeling of 5′-O-(4,4′-dimethoxytrityl)-2,3′-anhydrothymidine for [18F]FLT preparation. J Radioanal Nucl Chem 251:55–58

    Article  CAS  Google Scholar 

  10. Machulla HJ, Blocher A, Kuntzsch M, Piert, M, Wei R, Grierson JR (2000) Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem 243:843–846

    Article  CAS  Google Scholar 

  11. Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48:1151–1159

    PubMed  CAS  Google Scholar 

  12. Huovinen R, Leskinen-Kallio S, Nagren K, Lehikoinen P, Ruotsalainen U, Teras M (1993) Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. Br J Cancer 67:787–791

    PubMed  CAS  Google Scholar 

  13. Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ (1996) Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 2:933–939

    PubMed  CAS  Google Scholar 

  14. Schirrmeister H, Guhlmann A, Kotzerke J, et al. (1999) Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 17:2381–2389

    PubMed  CAS  Google Scholar 

  15. Beaney RP, Lammertsma AA, Jones T, McKenzie CG, Halnan KE (1994) Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma. Lancet 1:131–134

    Google Scholar 

  16. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T (1992) Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 52:1592–1597

    PubMed  CAS  Google Scholar 

  17. Lacan G, Kesner AL, Gangloff A, Zhang L, Czernin J, Melega W, Silverman DH (2005) Synthesis of 2-[(2-chloro-2′-[18F]fluoroethyl)amino]-2H-1,3,2-oxaphosphorinane-2-oxide (18F-fluorocyclophosphamide), a potential tracer for breast tumor prognostic imaging with PET. J Label Compd Radiopharm 48:635–643

    Article  CAS  Google Scholar 

  18. Kesner AL, Townsend A, Hsueh WA, et al. (2004) A non-invasive assay to predict chemotherapy response to 5-fluorouracil using [18F]-5-FU and PET. J Nucl Med 45:331P, (Abstract)

    Google Scholar 

  19. Hsueh WA, Gangloff A, Kesner AL, et al. (2004) Predicting chemotherapy response to paclitaxel using [18F]-fluoropaclitaxel and PET. J Nucl Med 45:38P, (Abstract)

    Google Scholar 

  20. Hsueh WA, Gangloff A, Kesner AL, Pio BS, Beryt MM, Pegram M, Czernin J, Phelps ME, Silverman DH (2005) Added value of [18F]-fluoropaclitaxel beyond tumor size as a predictor for paclitaxel resistance. J Nucl Med 46(S2):398P, (Abstract)

    Google Scholar 

  21. Hsueh WA, Gangloff A, Kesner AL, Beryt MM, Pegram M, Czernin J, Phelps ME, Silverman DH (2005) FDG and FLT microPET predictors of tumor response and survival following chemotherapy. J Nucl Med 46(S2):155P, (Abstract)

    Google Scholar 

  22. Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Czernin J, Pegram MD, Beryt M, Phelps ME, Silverman DH (2005) Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with [18F]-fluoropaclitaxel. J Nucl Med 46(11):1866–1871

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the UCLA Cyclotron staff for PET tracer production, and the UCLA Ahmanson Biological Imaging Center Technologists for their support in PET acquisition.

Author information

Authors and Affiliations

  1. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

    Betty S. Pio MS, Wei-Ann Hsueh BS, Nagichettiar Satyamurthy PhD, Johannes Czernin MD, Michael E. Phelps PhD & Daniel H. S. Silverman MD, PhD

  2. Department of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

    Cecilia K. Park MD, Richard Pietras MD & Mark D. Pegram MD

Authors
  1. Betty S. Pio MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cecilia K. Park MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Pietras MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei-Ann Hsueh BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nagichettiar Satyamurthy PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mark D. Pegram MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Johannes Czernin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michael E. Phelps PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daniel H. S. Silverman MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel H. S. Silverman MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pio, B.S., Park, C.K., Pietras, R. et al. Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy. Mol Imaging Biol 8, 36–42 (2006). https://doi.org/10.1007/s11307-005-0029-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-005-0029-9

Key words

Search

Navigation